Additional file 3: of Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study

Table S3. The characteristics and outcomes of alendronate-treated patients with and without bone loss. (DOCX 26 kb)